SCHEMBL4906352

SCHEMBL4906352

Cc1cccc(C(=O)Nc2cccc(Cl)c2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.64
HDAC6 Q9UBN7 1/20 0.64
AHR P35869 2/20 0.61
ALDH1A1 P00352 2/20 0.60
GRM5 P41594 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.59
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
TP53 P04637 1/20 0.58
NFKB1 P19838 1/20 0.58
MAPK1 P28482 1/20 0.58
NFKB2 Q00653 1/20 0.58
RELA Q04206 1/20 0.58
KDR P35968 1/20 0.58
THRB P10828 1/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
CNR2 P34972 1/20 0.57
P4HTM Q9NXG6 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7900424 0.87 ALDH1A1 (0.59) GRM4HDAC6AHRALDH1A1L3MBTL1
SCHEMBL30761113 0.84 POLB (0.77) ALDH1A1GRM5L3MBTL1NPC1RAB9A
SCHEMBL13201029 0.84 POLB (0.77) ALDH1A1GRM5L3MBTL1NPC1RAB9A
SCHEMBL31432059 0.83 GRM4 (0.66) GRM4HDAC6AHRALDH1A1L3MBTL1
SCHEMBL7913781 0.80 ALDH1A1 (0.52) GRM4HDAC6AHRALDH1A1L3MBTL1
SCHEMBL13148098 0.80 L3MBTL1 (0.54) GRM4HDAC6AHRALDH1A1L3MBTL1
SCHEMBL2530324 0.78 GRM4 (1.00) GRM4HDAC6AHRNPC1RAB9A
SCHEMBL29496401 0.78 GRM4 (1.00) GRM4HDAC6AHRNPC1RAB9A
SCHEMBL1795610 0.78 SMN1; SMN2 (0.51) GRM4HDAC6AHRALDH1A1L3MBTL1
SCHEMBL9906904 0.78 RAB9A (0.65) ALDH1A1GRM5NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858854-B1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-05-07 EP disclosed
US-20080269256-A1 PYRIDINE-2-CARBOXYAMIDE DERIVATIVES JAESCHKE GEORG 2008-10-30 US disclosed
US-7414060-B2 Pyridine-2-carboxyamide derivatives HOFFMANN-LA ROCHE INC. (US) 2008-08-19 US disclosed
EP-1858854-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2007-11-28 EP disclosed
WO-2006094639-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-14 WO disclosed
US-20060199960-A1 e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders HOFFMANN-LA ROCHE INC. 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269256-A1 PYRIDINE-2-CARBOXYAMIDE DERIVATIVES CNR2, CNR1, CHRNA2 GRM4 258/4885HDAC6 1415/4885AHR 1536/4885
US-20060199960-A1 e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders GRM3, GRM2, GRM1 GRM4 7/4885HDAC6 2008/4885AHR 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.